GNI Group（2160）株式概要ジーエヌアイグループ・リミテッドは、その子会社とともに、日本、中国、米国において、医薬品および生体材料の研究、開発、製造、販売を行っている。 詳細2160 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長5/6過去の実績0/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より65.4%で取引されている 収益は年間54.16%増加すると予測されています リスク分析JP市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る2160 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueJP¥Current PriceJP¥2.47k47.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-6b77b2016201920222025202620282031Revenue JP¥77.3bEarnings JP¥14.2bAdvancedSet Fair ValueView all narrativesGNI Group Ltd. 競合他社PeptiDreamSymbol: TSE:4587Market cap: JP¥123.3bHeartseedSymbol: TSE:219AMarket cap: JP¥37.8bJapan Tissue EngineeringSymbol: TSE:7774Market cap: JP¥25.7b3-D MatrixSymbol: TSE:7777Market cap: JP¥41.0b価格と性能株価の高値、安値、推移の概要GNI Group過去の株価現在の株価JP¥2,470.0052週高値JP¥3,845.0052週安値JP¥2,112.00ベータ1.241ヶ月の変化-12.84%3ヶ月変化-16.78%1年変化-33.69%3年間の変化64.67%5年間の変化16.90%IPOからの変化761.63%最新ニュースPrice Target Changed • Jun 09Price target increased by 16% to JP¥5,000Up from JP¥4,300, the current price target is provided by 1 analyst. New target price is 79% above last closing price of JP¥2,786. Stock is down 24% over the past year. The company is forecast to post earnings per share of JP¥49.70 next year compared to a net loss per share of JP¥80.89 last year.Reported Earnings • May 20First quarter 2026 earnings released: JP¥38.19 loss per share (vs JP¥10.57 loss in 1Q 2025)First quarter 2026 results: JP¥38.19 loss per share (further deteriorated from JP¥10.57 loss in 1Q 2025). Revenue: JP¥5.53b (up 3.9% from 1Q 2025). Net loss: JP¥2.13b (loss widened 301% from 1Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.Board Change • May 18Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Outside Director Hironao Yazaki was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.ライブニュース • May 08Gyre Therapeutics Expands With US$300 Million Cullgen Acquisition to Strengthen U.S.-China PipelineGyre Therapeutics, a GNI Group subsidiary, has completed a US$300 million all‑stock acquisition of clinical-stage biopharma company Cullgen Inc. Following the deal, former Cullgen CEO Ying Luo becomes President and CEO of Gyre, while Ping Zhang becomes Chairman, with Gyre retaining its Nasdaq listing under the ticker GYRE. The combined group now brings together ETUARY®, late-stage candidate F351 and Cullgen’s protein degrader and DAC platforms within a single U.S.-China biopharma platform. For you as an investor, the completion of the Cullgen acquisition means GNI’s ecosystem now spans a marketed product, an advanced late-stage pipeline asset and early-stage discovery platforms under Gyre Therapeutics. The all-stock structure keeps cash inside the group while folding Cullgen’s research capabilities and clinical programs into Gyre’s portfolio. The management reshuffle, with Ying Luo taking the helm at Gyre and Ping Zhang assuming the chairman role, points to a focus on tighter operational control and clearer leadership around the combined U.S.-China setup. Investors may monitor how the group integrates Cullgen’s platforms, progresses F351 and uses ETUARY® alongside the protein degrader and DAC technologies to support pipeline development and potential partnerships.Board Change • Mar 31Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent External Director Masahiro Matsuoka was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.最新情報をもっと見るRecent updatesPrice Target Changed • Jun 09Price target increased by 16% to JP¥5,000Up from JP¥4,300, the current price target is provided by 1 analyst. New target price is 79% above last closing price of JP¥2,786. Stock is down 24% over the past year. The company is forecast to post earnings per share of JP¥49.70 next year compared to a net loss per share of JP¥80.89 last year.Reported Earnings • May 20First quarter 2026 earnings released: JP¥38.19 loss per share (vs JP¥10.57 loss in 1Q 2025)First quarter 2026 results: JP¥38.19 loss per share (further deteriorated from JP¥10.57 loss in 1Q 2025). Revenue: JP¥5.53b (up 3.9% from 1Q 2025). Net loss: JP¥2.13b (loss widened 301% from 1Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.Board Change • May 18Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Outside Director Hironao Yazaki was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.ライブニュース • May 08Gyre Therapeutics Expands With US$300 Million Cullgen Acquisition to Strengthen U.S.-China PipelineGyre Therapeutics, a GNI Group subsidiary, has completed a US$300 million all‑stock acquisition of clinical-stage biopharma company Cullgen Inc. Following the deal, former Cullgen CEO Ying Luo becomes President and CEO of Gyre, while Ping Zhang becomes Chairman, with Gyre retaining its Nasdaq listing under the ticker GYRE. The combined group now brings together ETUARY®, late-stage candidate F351 and Cullgen’s protein degrader and DAC platforms within a single U.S.-China biopharma platform. For you as an investor, the completion of the Cullgen acquisition means GNI’s ecosystem now spans a marketed product, an advanced late-stage pipeline asset and early-stage discovery platforms under Gyre Therapeutics. The all-stock structure keeps cash inside the group while folding Cullgen’s research capabilities and clinical programs into Gyre’s portfolio. The management reshuffle, with Ying Luo taking the helm at Gyre and Ping Zhang assuming the chairman role, points to a focus on tighter operational control and clearer leadership around the combined U.S.-China setup. Investors may monitor how the group integrates Cullgen’s platforms, progresses F351 and uses ETUARY® alongside the protein degrader and DAC technologies to support pipeline development and potential partnerships.Board Change • Mar 31Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent External Director Masahiro Matsuoka was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Reported Earnings • Feb 14Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: JP¥84.08 loss per share (down from JP¥21.96 profit in FY 2024). Revenue: JP¥26.8b (up 14% from FY 2024). Net loss: JP¥4.41b (down JP¥5.51b from profit in FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.お知らせ • Feb 13GNI Group Ltd., Annual General Meeting, Mar 26, 2026GNI Group Ltd., Annual General Meeting, Mar 26, 2026.お知らせ • Jan 23+ 1 more updateGNI Group Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2025GNI Group Ltd. revised consolidated earnings guidance for the fiscal year ending December 31, 2025. For the year, the group now expects Revenue of JPY 26,841 million against previous guidance of JPY 28,733 million, operating loss of JPY 2,725 million against previous guidance of operating profit of JPY 23,217 million, Loss Before Income Taxes of JPY 3,795 million against previous guidance of Profit Before Income Taxes of JPY 22,541 million, Loss attributable to the owners of parent of JPY 3,420 million against previous guidance of profit Attributable to Owners of the Parent of JPY 12,058 million, basic loss per share of JPY 65.18 against previous guidance of basic earnings per share of JPY 240.42. Reasons for Revision: Revenue has been revised primarily due to the pharmaceutical business, as Etorel® (nintedanib), which was launched in 2025, is now expected to fall below the initial budget. Meanwhile, in the pharmaceutical business as a whole, sales of the Company's core product, ETUARY®, continue to perform steadily, and revenue is expected to reach a record high for the 12th consecutive fiscal year since its launch in 2014. In addition, in the Medtech business, following the acquisition of Berkeley Advanced Biomaterials (BAB) in 2017, revenue is expected to reach record highs for the 9th consecutive fiscal year. As a result, consolidated revenue is expected to increase by JPY 3,230 million compared to the previous fiscal year, to JPY 26,841 million. Profit: Deferral of the listing of consolidated subsidiary Cullgen. In the Group's pharmaceutical (Biotech) business, Cullgen Inc. ("Cullgen"), a core subsidiary, has been pursuing a listing on the NASDAQ market in the United States, subject to approval of a reverse merger transaction by the China Securities Regulatory Commission ("CSRC"). The Group had expected the review to be completed and the listing to be achieved within the fiscal year ending December 2025. However, as the approval remains pending at this time, the listing gain of JPY 22,854 million that had been included in the profit forecast for the fiscal year ending December 2025 has been excluded. Furthermore, while the initial forecast assumed Cullgen would transition to an equity-method affiliate following its listing, a change in the timing of the listing has resulted in Cullgen remaining a consolidated subsidiary for the second half of the fiscal year. Accordingly, its full-year estimated operating loss of JPY 3,996 million is now reflected in this revised forecast. Impairment Losses: As a result of impairment tests conducted by an independent third-party firm, the recoverable amounts of goodwill related to MICREN Healthcare Co. Ltd., intangible assets related to Shanghai Genomics Technology Ltd., and fixed assets related to Shanghai Rui Fu International Trade Co. Ltd. were determined to be below their carrying amounts, and an impairment loss totaling JPY 468 million is expected to be recognized. Furthermore, with respect to the transaction review related to Cullgen's listing, the approval process remains ongoing. As disclosed on December 19, 2025, the Group is continuing its efforts toward the early realization of the listing while considering alternative options. If the listing is realized in the future, any listing gain will be recognized in the financial results for the accounting period in which the listing occurs; however, the actual amount of such gain will vary depending on the initial public offering price on the listing date as well as foreign exchange movements.お知らせ • Jan 10GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd.GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd. on December 29, 2025. A cash consideration will be paid by GNI Group Ltd towards common equity of ZOO LABO Co., Ltd. The funds were sourced from the proceeds raised through the overseas public offering conducted in July 2025. GNI Group Ltd. (TSE:2160) completed the acquisition of ZOO LABO Co., Ltd. on December 29, 2025.分析記事 • Jan 05Does GNI Group (TSE:2160) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Dec 27GNI Group Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026GNI Group Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: JP¥7.84 (vs JP¥19.48 in 3Q 2024)Third quarter 2025 results: EPS: JP¥7.84 (down from JP¥19.48 in 3Q 2024). Revenue: JP¥7.11b (up 30% from 3Q 2024). Net income: JP¥420.0m (down 57% from 3Q 2024). Profit margin: 5.9% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.お知らせ • Sep 27GNI Group Ltd. to Report Q3, 2025 Results on Nov 14, 2025GNI Group Ltd. announced that they will report Q3, 2025 results on Nov 14, 2025Reported Earnings • Aug 15Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2025 results: JP¥7.62 loss per share (improved from JP¥22.48 loss in 2Q 2024). Revenue: JP¥6.93b (up 20% from 2Q 2024). Net loss: JP¥384.7m (loss narrowed 66% from 2Q 2024). Revenue missed analyst estimates by 49%. Earnings per share (EPS) exceeded analyst estimates by 93%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 21% per year.お知らせ • Jul 23GNI Group Ltd. has filed a Follow-on Equity Offering.GNI Group Ltd. has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 4,000,000分析記事 • Jul 01GNI Group (TSE:2160) Has Debt But No Earnings; Should You Worry?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Jun 27GNI Group Ltd. to Report Q2, 2025 Results on Aug 14, 2025GNI Group Ltd. announced that they will report Q2, 2025 results on Aug 14, 2025お知らせ • Jun 05Gyre Pharmaceuticals Co., Ltd. Announces Launch of Etorel (Nintedanib Esilate Soft Capsules) by Gyre PharmaceuticalsGNI Group Ltd. announced that its core subsidiary, Gyre Pharmaceuticals Co. Ltd., has commenced sales of "Etorel" (Nintedanib Esilate Soft Capsules), as announced on May 8, 2024, in the press release titled "Notice Regarding License Agreement entered into by GNI's Consolidated Subsidiary, Gyre Pharmaceuticals Co. Ltd., as it has secured the only two approved drugs for pulmonary fibrosis worldwide. This achievement has strategic significance in strengthening its position as a global leading company in the treatment of pulmonary fibrosis, continuously expanding its market share, and enhancing its presence in the field of interstitial lung diseases. The market for pulmonary fibrosis is large, with many unmet clinical needs remaining. Nintedanib Esilates Soft Capsules are approved not only for idiopathic pulmonary fibrosis (IPF), but also for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive fibrosing interstitial lung disease (PF-ILD). The impact of this development on the company's performance has already been factored into the current consolidated earnings forecast. The impact of this development on The company's performance has already beenfactored into the current consolidated earnings forecasts. The impact of this development On the company's performance has already be factored into the current consolidated Earn forecast. The impact of this develop on the company's performance has also been factored into the current consolidate earnings forecast. The impact of This development on the company's performance have already been factored into the currently consolidated earnings forecast. The impact the development on the company's performance is already been factored into the existing consolidated earnings forecast.Price Target Changed • May 27Price target increased by 11% to JP¥4,000Up from JP¥3,600, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of JP¥4,110. Stock is up 96% over the past year. The company is forecast to post earnings per share of JP¥215 for next year compared to JP¥21.96 last year.分析記事 • May 26GNI Group Ltd.'s (TSE:2160) Shares Bounce 52% But Its Business Still Trails The IndustryGNI Group Ltd. ( TSE:2160 ) shareholders are no doubt pleased to see that the share price has bounced 52% in the last...Reported Earnings • May 17First quarter 2025 earnings released: JP¥10.56 loss per share (vs JP¥29.17 profit in 1Q 2024)First quarter 2025 results: JP¥10.56 loss per share (down from JP¥29.17 profit in 1Q 2024). Revenue: JP¥5.32b (down 11% from 1Q 2024). Net loss: JP¥530.0m (down 137% from profit in 1Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.Major Estimate Revision • May 15Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from JP¥48.7b to JP¥43.0b. EPS estimate increased from JP¥195 to JP¥217 per share. Net income forecast to grow 869% next year vs 6.9% growth forecast for Biotechs industry in Japan. Consensus price target down from JP¥3,850 to JP¥3,600. Share price rose 3.5% to JP¥2,396 over the past week.分析記事 • Apr 11GNI Group Ltd. (TSE:2160) Might Not Be As Mispriced As It Looks After Plunging 28%Unfortunately for some shareholders, the GNI Group Ltd. ( TSE:2160 ) share price has dived 28% in the last thirty days...お知らせ • Apr 10GNI Group Ltd. to Report Q1, 2025 Results on May 15, 2025GNI Group Ltd. announced that they will report Q1, 2025 results on May 15, 2025Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 29%After last week's 29% share price decline to JP¥1,490, the stock trades at a forward P/E ratio of 8x. Average trailing P/E is 31x in the Biotechs industry in Asia. Total returns to shareholders of 13% over the past three years.Reported Earnings • Apr 05Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: JP¥21.96 (down from JP¥170 in FY 2023). Revenue: JP¥23.6b (down 9.2% from FY 2023). Net income: JP¥1.10b (down 86% from FY 2023). Profit margin: 4.7% (down from 31% in FY 2023). Revenue missed analyst estimates by 35%. Earnings per share (EPS) also missed analyst estimates by 88%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Feb 27Now 23% undervaluedOver the last 90 days, the stock has risen 4.5% to JP¥3,450. The fair value is estimated to be JP¥4,465, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 69%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings are also forecast to grow by 34% per annum over the same time period.分析記事 • Feb 26GNI Group's (TSE:2160) Weak Earnings May Only Reveal A Part Of The Whole PictureThe subdued market reaction suggests that GNI Group Ltd.'s ( TSE:2160 ) recent earnings didn't contain any surprises...分析記事 • Feb 21GNI Group Ltd.'s (TSE:2160) Shares Leap 25% Yet They're Still Not Telling The Full StoryDespite an already strong run, GNI Group Ltd. ( TSE:2160 ) shares have been powering on, with a gain of 25% in the last...お知らせ • Feb 18GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2025GNI Group Ltd. provided consolidated earnings guidance for the full year ending December 31, 2025. For the year, the company expects revenue of JPY 28,733 million, operating profit of JPY 23,217 million, profit for the year of JPY 15,868 million and basic earnings per share of JPY 240.42.分析記事 • Feb 18GNI Group Ltd. Just Missed Earnings - But Analysts Have Updated Their ModelsGNI Group Ltd. ( TSE:2160 ) missed earnings with its latest annual results, disappointing overly-optimistic...お知らせ • Feb 17GNI Group Ltd., Annual General Meeting, Mar 27, 2025GNI Group Ltd., Annual General Meeting, Mar 27, 2025.Reported Earnings • Feb 17Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: JP¥19.54 (down from JP¥170 in FY 2023). Revenue: JP¥23.6b (down 9.2% from FY 2023). Net income: JP¥977.0m (down 88% from FY 2023). Profit margin: 4.1% (down from 31% in FY 2023). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 35%. Earnings per share (EPS) also missed analyst estimates by 89%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 03GNI Group Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025GNI Group Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥3,295, the stock trades at a forward P/E ratio of 15x. Average trailing P/E is 22x in the Biotechs industry in Japan. Total returns to shareholders of 132% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥1,749 per share.Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: JP¥19.48 (vs JP¥11.67 in 3Q 2023)Third quarter 2024 results: EPS: JP¥19.48 (up from JP¥11.67 in 3Q 2023). Revenue: JP¥5.46b (down 15% from 3Q 2023). Net income: JP¥975.0m (up 76% from 3Q 2023). Profit margin: 18% (up from 8.6% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 01GNI Group Ltd. to Report Q3, 2024 Results on Nov 14, 2024GNI Group Ltd. announced that they will report Q3, 2024 results on Nov 14, 2024分析記事 • Sep 20After Leaping 48% GNI Group Ltd. (TSE:2160) Shares Are Not Flying Under The RadarGNI Group Ltd. ( TSE:2160 ) shareholders would be excited to see that the share price has had a great month, posting a...Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 19%After last week's 19% share price gain to JP¥2,495, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 17x in the Biotechs industry in Japan. Total returns to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥1,655 per share.分析記事 • Aug 27GNI Group's (TSE:2160) Shareholders Should Assess Earnings With CautionDespite posting strong earnings, GNI Group Ltd.'s ( TSE:2160 ) stock didn't move much over the last week. We looked...Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to JP¥2,241, the stock trades at a forward P/E ratio of 10x. Average trailing P/E is 14x in the Biotechs industry in Japan. Total returns to shareholders of 40% over the past three years.Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: JP¥3.31 (vs JP¥34.98 in 2Q 2023)Second quarter 2024 results: EPS: JP¥3.31 (down from JP¥34.98 in 2Q 2023). Revenue: JP¥5.87b (down 41% from 2Q 2023). Net income: JP¥165.1m (down 90% from 2Q 2023). Profit margin: 2.8% (down from 17% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 07Investor sentiment deteriorates as stock falls 24%After last week's 24% share price decline to JP¥1,732, the stock trades at a forward P/E ratio of 9x. Average trailing P/E is 51x in the Biotechs industry in Japan. Total returns to shareholders of 3.0% over the past three years.分析記事 • Aug 06GNI Group Ltd. (TSE:2160) Stock's 37% Dive Might Signal An Opportunity But It Requires Some ScrutinyGNI Group Ltd. ( TSE:2160 ) shareholders that were waiting for something to happen have been dealt a blow with a 37...New Risk • Aug 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). High level of non-cash earnings (41% accrual ratio). Minor Risk Shareholders have been diluted in the past year (5.4% increase in shares outstanding).Valuation Update With 7 Day Price Move • Jul 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥2,233, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 94x in the Biotechs industry in Japan. Total returns to shareholders of 21% over the past three years.分析記事 • Jun 20Investors Continue Waiting On Sidelines For GNI Group Ltd. (TSE:2160)GNI Group Ltd.'s ( TSE:2160 ) price-to-sales (or "P/S") ratio of 4.4x might make it look like a strong buy right now...お知らせ • Jun 02GNI Group Ltd. to Report Q2, 2024 Results on Aug 14, 2024GNI Group Ltd. announced that they will report Q2, 2024 results on Aug 14, 2024Board Change • May 19High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Executive officer, CFO & Director Toshiya Kitagawa was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.分析記事 • Apr 12Is GNI Group (TSE:2160) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...お知らせ • Mar 27GNI Group Ltd. to Report Q1, 2024 Results on May 15, 2024GNI Group Ltd. announced that they will report Q1, 2024 results on May 15, 2024分析記事 • Mar 19News Flash: Analysts Just Made An Incredible Upgrade To Their GNI Group Ltd. (TSE:2160) ForecastsGNI Group Ltd. ( TSE:2160 ) shareholders will have a reason to smile today, with the covering analyst making...Major Estimate Revision • Mar 19Consensus revenue estimates increase by 38%The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from JP¥28.8b to JP¥39.6b. EPS estimate increased from JP¥37.00 to JP¥143 per share. Net income forecast to shrink 12% next year vs 25% growth forecast for Biotechs industry in Japan . Consensus price target up from JP¥3,000 to JP¥4,100. Share price rose 2.8% to JP¥3,130 over the past week.分析記事 • Feb 28Further Upside For GNI Group Ltd. (TSE:2160) Shares Could Introduce Price Risks After 40% BounceGNI Group Ltd. ( TSE:2160 ) shares have had a really impressive month, gaining 40% after a shaky period beforehand. The...Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improves as stock rises 43%After last week's 43% share price gain to JP¥3,615, the stock trades at a forward P/E ratio of 98x. Average trailing P/E is 69x in the Biotechs industry in Japan. Total returns to shareholders of 92% over the past three years.Reported Earnings • Feb 16Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: EPS: JP¥170 (up from JP¥8.17 in FY 2022). Revenue: JP¥26.0b (up 49% from FY 2022). Net income: JP¥8.09b (up JP¥7.71b from FY 2022). Profit margin: 31% (up from 2.2% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates significantly. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 15GNI Group Ltd., Annual General Meeting, Mar 28, 2024GNI Group Ltd., Annual General Meeting, Mar 28, 2024.New Risk • Dec 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Shareholders have been diluted in the past year (4.7% increase in shares outstanding).お知らせ • Dec 05GNI Group Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024GNI Group Ltd. announced that they will report fiscal year 2023 results on Feb 14, 2024Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: JP¥11.67 (vs JP¥8.40 in 3Q 2022)Third quarter 2023 results: EPS: JP¥11.67 (up from JP¥8.40 in 3Q 2022). Revenue: JP¥6.45b (up 40% from 3Q 2022). Net income: JP¥554.0m (up 39% from 3Q 2022). Profit margin: 8.6% (down from 8.7% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.お知らせ • Sep 29+ 1 more updateGNI Group Ltd. Announces New Management StructureGNI Group Co. Ltd. announced that Board of Directors has resolved at a meeting on September 28, 2023 to change the responsibilities of directors and executive officers effective October 1, 2023. Change of the responsibilities of directors and executive officers: Kan-ichiro Suzuki is now Director, Executive Officer, Vice President from previous position of Director, Executive Officer, CFO (Chief Financial Officer) and Toshiya Kitagawa is now Executive Officer, CFO (Chief Financial Officer) from previous position of Executive Officer, CSO (Chief Strategy Officer).Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 44%After last week's 44% share price gain to JP¥1,970, the stock trades at a forward P/E ratio of 122x. Average forward P/E is 29x in the Biotechs industry in Asia. Total loss to shareholders of 25% over the past three years.New Risk • Aug 15New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 30% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (30% accrual ratio).Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: JP¥34.96 (vs JP¥6.85 in 2Q 2022)Second quarter 2023 results: EPS: JP¥34.96 (up from JP¥6.85 in 2Q 2022). Revenue: JP¥9.89b (up 134% from 2Q 2022). Net income: JP¥1.66b (up 411% from 2Q 2022). Profit margin: 17% (up from 7.7% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Major Estimate Revision • Aug 04Consensus EPS estimates fall by 47%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from JP¥68.00 to JP¥36.00. Revenue forecast unchanged from JP¥24.8b at last update. Net income forecast to grow 3,411% next year vs 33% growth forecast for Biotechs industry in Japan. Consensus price target of JP¥1,500 unchanged from last update. Share price rose 10% to JP¥1,346 over the past week.お知らせ • Jul 04Gni Group Ltd. Announces Notice of Executive Officer AppointmentJuly 3, 2023, GNI Group Ltd. ("the Group") announced the appointment of Toshiya Kitagawa as Chief Strategy Officer (CSO) with the aim of accelerating the global business growth of the Group under a resolution of the Board of Directors dated on July 3, 2023. Career summary of Toshiya Kitagawa: April 2000: Japan Bond Trading Co. Ltd. April 2002: Totan ICAP Co. Ltd. February 2003: Deal Max Co. Ltd. October 2008: OAG Certified Public Tax Accountant's Corporation Business Development Manager. April 2009: Takara Leben Co. Ltd. Director, Executive Officer, General Manager of Corporate Planning Office. April 2017: Hoosiers Holdings Co. Ltd. General Manager of Group Strategy Office. January 2019: BASE Co. Ltd. CEO. March 2023: Eltes Co. Ltd. Deputy General Manager of Corporate Planning Office. July 2023: GNI Group Ltd., SO.New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.2% net profit margin).Reported Earnings • May 19First quarter 2023 earnings released: JP¥0.042 loss per share (vs JP¥7.40 profit in 1Q 2022)First quarter 2023 results: JP¥0.042 loss per share (down from JP¥7.40 profit in 1Q 2022). Revenue: JP¥4.21b (up 6.9% from 1Q 2022). Net loss: JP¥2.00m (down 101% from profit in 1Q 2022). Profit margin: 0% (down from 8.9% in 1Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.お知らせ • May 10Beijing Continent Achieves Mid-Point Subject Enrollment for F351 Phase III Clinical Trial in ChinaGNI Group Ltd. provided an update on the subject enrollment in Phase III clinical trial in China of F351 (generic name: Hydronidone) for HBV-induced liver fibrosis conducted by one of main subsidiaries, Beijing Continent Pharmaceuticals Co. Ltd. As of May 19, 2023, Continent has completed the enrollments of 124 subjects, which is 50% of the target enrollment.Board Change • Apr 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Outside Director Kanako Kikuchi was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 18Full year 2022 earnings released: EPS: JP¥9.61 (vs JP¥22.72 in FY 2021)Full year 2022 results: EPS: JP¥9.61 (down from JP¥22.72 in FY 2021). Revenue: JP¥17.4b (up 37% from FY 2021). Net income: JP¥456.0m (down 57% from FY 2021). Profit margin: 2.6% (down from 8.4% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Feb 16+ 1 more updateGNI Group Ltd. to Report Fiscal Year 2022 Final Results on Mar 31, 2023GNI Group Ltd. announced that they will report fiscal year 2022 final results on Mar 31, 2023お知らせ • Feb 15GNI Group Ltd., Annual General Meeting, Mar 30, 2023GNI Group Ltd., Annual General Meeting, Mar 30, 2023.Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥1,393, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 27x in the Biotechs industry in Asia. Total loss to shareholders of 47% over the past three years.お知らせ • Dec 06GNI Group Ltd. to Report Fiscal Year 2022 Results on Feb 15, 2023GNI Group Ltd. announced that they will report fiscal year 2022 results on Feb 15, 2023Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: JP¥8.42 (vs JP¥7.42 in 3Q 2021)Third quarter 2022 results: EPS: JP¥8.42 (up from JP¥7.42 in 3Q 2021). Revenue: JP¥4.61b (up 50% from 3Q 2021). Net income: JP¥400.0m (up 14% from 3Q 2021). Profit margin: 8.7% (down from 12% in 3Q 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 17Second quarter 2022 earnings released: EPS: JP¥6.85 (vs JP¥10.76 in 2Q 2021)Second quarter 2022 results: EPS: JP¥6.85 (down from JP¥10.76 in 2Q 2021). Revenue: JP¥4.22b (up 63% from 2Q 2021). Net income: JP¥325.0m (down 36% from 2Q 2021). Profit margin: 7.7% (down from 20% in 2Q 2021). Over the next year, revenue is forecast to grow 25%, compared to a 182% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Major Estimate Revision • Aug 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from JP¥15.7b to JP¥16.4b. EPS estimate fell from JP¥58.00 to JP¥23.13 per share. Net income forecast to grow 21% next year vs 29% growth forecast for Biotechs industry in Japan. Consensus price target of JP¥2,100 unchanged from last update. Share price was steady at JP¥1,977 over the past week.Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to JP¥1,526, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 26x in the Biotechs industry in Asia. Total returns to shareholders of 5.5% over the past three years.Valuation Update With 7 Day Price Move • May 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to JP¥1,210, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 23x in the Biotechs industry in Asia. Total returns to shareholders of 29% over the past three years.Price Target Changed • Apr 27Price target decreased to JP¥2,100Down from JP¥2,500, the current price target is provided by 1 analyst. New target price is 82% above last closing price of JP¥1,156. Stock is down 43% over the past year. The company is forecast to post earnings per share of JP¥58.00 for next year compared to JP¥22.72 last year.Reported Earnings • Apr 02Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: JP¥22.72 (down from JP¥28.96 in FY 2020). Revenue: JP¥12.7b (up 30% from FY 2020). Net income: JP¥1.07b (down 15% from FY 2020). Profit margin: 8.4% (down from 13% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 27%. Over the next year, revenue is forecast to grow 24%, compared to a 3,392% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥1,416, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 29x in the Biotechs industry in Asia. Total returns to shareholders of 43% over the past three years.Reported Earnings • Feb 16Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: JP¥22.72 (down from JP¥28.96 in FY 2020). Revenue: JP¥12.7b (up 30% from FY 2020). Net income: JP¥1.07b (down 15% from FY 2020). Profit margin: 8.4% (down from 13% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 27%. Over the next year, revenue is forecast to grow 24%, compared to a 1,669% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to JP¥1,193, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 27x in the Biotechs industry in Asia. Total returns to shareholders of 11% over the past three years.Reported Earnings • Nov 18Third quarter 2021 earnings released: EPS JP¥7.44 (vs JP¥5.11 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥3.07b (up 19% from 3Q 2020). Net income: JP¥353.0m (up 59% from 3Q 2020). Profit margin: 12% (up from 8.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to JP¥1,586, the stock trades at a trailing P/E ratio of 44.8x. Average trailing P/E is 36x in the Biotechs industry in Japan. Total returns to shareholders of 44% over the past three years.Reported Earnings • Apr 06Full year 2020 earnings released: EPS JP¥28.96 (vs JP¥4.28 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥9.77b (up 31% from FY 2019). Net income: JP¥1.26b (up JP¥1.08b from FY 2019). Profit margin: 13% (up from 2.4% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥2,315, the stock trades at a trailing P/E ratio of 79.9x. Average trailing P/E is 112x in the Biotechs industry in Japan. Total returns to shareholders of 27% over the past three years.Reported Earnings • Feb 14Full year 2020 earnings released: EPS JP¥25.05 (vs JP¥4.28 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥9.77b (up 31% from FY 2019). Net income: JP¥1.09b (up JP¥907.0m from FY 2019). Profit margin: 11% (up from 2.4% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 22New 90-day high: JP¥2,179The company is up 3.0% from its price of JP¥2,108 on 23 October 2020. The Japanese market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.株主還元2160JP BiotechsJP 市場7D-1.0%-1.2%4.7%1Y-33.7%-35.3%46.9%株主還元を見る業界別リターン: 2160過去 1 年間で-35.3 % の収益を上げたJP Biotechs業界を上回りました。リターン対市場: 2160は、過去 1 年間で46.9 % のリターンを上げたJP市場を下回りました。価格変動Is 2160's price volatile compared to industry and market?2160 volatility2160 Average Weekly Movement8.6%Biotechs Industry Average Movement7.4%Market Average Movement4.6%10% most volatile stocks in JP Market9.3%10% least volatile stocks in JP Market2.3%安定した株価: 2160の株価は、 JP市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 2160の weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてJPの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2001990Ying Luowww.gnipharma.comジーエヌアイグループは子会社とともに、日本、中国、米国で医薬品と生体材料の研究、開発、製造、販売を行っている。医薬品事業と医療機器事業の2つのセグメントで事業を展開している。特発性肺線維症治療薬「エテュアリー」、骨欠損治療薬「H-ジェニン・クラッシュミックス」、急性・慢性創傷治療薬「アルティプライ」、整形生物学的製剤などを提供している。また、じん肺、皮膚筋炎性間質性肺疾患、全身性硬化症関連間質性肺疾患の治療薬として第III相臨床試験中のETUARY、B型慢性肝炎肝線維症の治療薬として第III相臨床試験中のF351も開発している。さらに、免疫関連肺炎を伴う、または伴わない放射線誘発性肺障害の治療薬として第Ⅱ相臨床試験中のETUARY、急性肝不全および急性-慢性肝不全の治療薬として第Ⅱ相臨床試験中のF573、MASH進行性肝線維症の治療薬として第Ⅰ相臨床試験中のF351、肺動脈性肺高血圧症の治療薬として第Ⅰ相臨床試験中のF230の開発にも携わっている。さらに、急性および慢性疼痛の治療薬として第Ia相臨床試験中のCG001419、固形癌の治療薬として第Ia相臨床試験中のCG001419、白血病およびMYC+癌の治療薬として第Ia相臨床試験中のCG009301を開発している。同社は2001年に設立され、日本の中央区に本社を置いている。もっと見るGNI Group Ltd. 基礎のまとめGNI Group の収益と売上を時価総額と比較するとどうか。2160 基礎統計学時価総額JP¥141.04b収益（TTM）-JP¥6.01b売上高(TTM)JP¥27.05b5.1xP/Sレシオ-22.9xPER（株価収益率2160 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計2160 損益計算書（TTM）収益JP¥27.05b売上原価JP¥7.14b売上総利益JP¥19.90bその他の費用JP¥25.91b収益-JP¥6.01b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-107.64グロス・マージン73.59%純利益率-22.21%有利子負債／自己資本比率7.6%2160 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/22 01:23終値2026/06/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GNI Group Ltd. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Stephen BarkerJefferies LLCYuriko IshidaMizuho Securities Co., Ltd.null nullStorm Research Limited
Price Target Changed • Jun 09Price target increased by 16% to JP¥5,000Up from JP¥4,300, the current price target is provided by 1 analyst. New target price is 79% above last closing price of JP¥2,786. Stock is down 24% over the past year. The company is forecast to post earnings per share of JP¥49.70 next year compared to a net loss per share of JP¥80.89 last year.
Reported Earnings • May 20First quarter 2026 earnings released: JP¥38.19 loss per share (vs JP¥10.57 loss in 1Q 2025)First quarter 2026 results: JP¥38.19 loss per share (further deteriorated from JP¥10.57 loss in 1Q 2025). Revenue: JP¥5.53b (up 3.9% from 1Q 2025). Net loss: JP¥2.13b (loss widened 301% from 1Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.
Board Change • May 18Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Outside Director Hironao Yazaki was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
ライブニュース • May 08Gyre Therapeutics Expands With US$300 Million Cullgen Acquisition to Strengthen U.S.-China PipelineGyre Therapeutics, a GNI Group subsidiary, has completed a US$300 million all‑stock acquisition of clinical-stage biopharma company Cullgen Inc. Following the deal, former Cullgen CEO Ying Luo becomes President and CEO of Gyre, while Ping Zhang becomes Chairman, with Gyre retaining its Nasdaq listing under the ticker GYRE. The combined group now brings together ETUARY®, late-stage candidate F351 and Cullgen’s protein degrader and DAC platforms within a single U.S.-China biopharma platform. For you as an investor, the completion of the Cullgen acquisition means GNI’s ecosystem now spans a marketed product, an advanced late-stage pipeline asset and early-stage discovery platforms under Gyre Therapeutics. The all-stock structure keeps cash inside the group while folding Cullgen’s research capabilities and clinical programs into Gyre’s portfolio. The management reshuffle, with Ying Luo taking the helm at Gyre and Ping Zhang assuming the chairman role, points to a focus on tighter operational control and clearer leadership around the combined U.S.-China setup. Investors may monitor how the group integrates Cullgen’s platforms, progresses F351 and uses ETUARY® alongside the protein degrader and DAC technologies to support pipeline development and potential partnerships.
Board Change • Mar 31Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent External Director Masahiro Matsuoka was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Price Target Changed • Jun 09Price target increased by 16% to JP¥5,000Up from JP¥4,300, the current price target is provided by 1 analyst. New target price is 79% above last closing price of JP¥2,786. Stock is down 24% over the past year. The company is forecast to post earnings per share of JP¥49.70 next year compared to a net loss per share of JP¥80.89 last year.
Reported Earnings • May 20First quarter 2026 earnings released: JP¥38.19 loss per share (vs JP¥10.57 loss in 1Q 2025)First quarter 2026 results: JP¥38.19 loss per share (further deteriorated from JP¥10.57 loss in 1Q 2025). Revenue: JP¥5.53b (up 3.9% from 1Q 2025). Net loss: JP¥2.13b (loss widened 301% from 1Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.
Board Change • May 18Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Outside Director Hironao Yazaki was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
ライブニュース • May 08Gyre Therapeutics Expands With US$300 Million Cullgen Acquisition to Strengthen U.S.-China PipelineGyre Therapeutics, a GNI Group subsidiary, has completed a US$300 million all‑stock acquisition of clinical-stage biopharma company Cullgen Inc. Following the deal, former Cullgen CEO Ying Luo becomes President and CEO of Gyre, while Ping Zhang becomes Chairman, with Gyre retaining its Nasdaq listing under the ticker GYRE. The combined group now brings together ETUARY®, late-stage candidate F351 and Cullgen’s protein degrader and DAC platforms within a single U.S.-China biopharma platform. For you as an investor, the completion of the Cullgen acquisition means GNI’s ecosystem now spans a marketed product, an advanced late-stage pipeline asset and early-stage discovery platforms under Gyre Therapeutics. The all-stock structure keeps cash inside the group while folding Cullgen’s research capabilities and clinical programs into Gyre’s portfolio. The management reshuffle, with Ying Luo taking the helm at Gyre and Ping Zhang assuming the chairman role, points to a focus on tighter operational control and clearer leadership around the combined U.S.-China setup. Investors may monitor how the group integrates Cullgen’s platforms, progresses F351 and uses ETUARY® alongside the protein degrader and DAC technologies to support pipeline development and potential partnerships.
Board Change • Mar 31Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent External Director Masahiro Matsuoka was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Reported Earnings • Feb 14Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: JP¥84.08 loss per share (down from JP¥21.96 profit in FY 2024). Revenue: JP¥26.8b (up 14% from FY 2024). Net loss: JP¥4.41b (down JP¥5.51b from profit in FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
お知らせ • Feb 13GNI Group Ltd., Annual General Meeting, Mar 26, 2026GNI Group Ltd., Annual General Meeting, Mar 26, 2026.
お知らせ • Jan 23+ 1 more updateGNI Group Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2025GNI Group Ltd. revised consolidated earnings guidance for the fiscal year ending December 31, 2025. For the year, the group now expects Revenue of JPY 26,841 million against previous guidance of JPY 28,733 million, operating loss of JPY 2,725 million against previous guidance of operating profit of JPY 23,217 million, Loss Before Income Taxes of JPY 3,795 million against previous guidance of Profit Before Income Taxes of JPY 22,541 million, Loss attributable to the owners of parent of JPY 3,420 million against previous guidance of profit Attributable to Owners of the Parent of JPY 12,058 million, basic loss per share of JPY 65.18 against previous guidance of basic earnings per share of JPY 240.42. Reasons for Revision: Revenue has been revised primarily due to the pharmaceutical business, as Etorel® (nintedanib), which was launched in 2025, is now expected to fall below the initial budget. Meanwhile, in the pharmaceutical business as a whole, sales of the Company's core product, ETUARY®, continue to perform steadily, and revenue is expected to reach a record high for the 12th consecutive fiscal year since its launch in 2014. In addition, in the Medtech business, following the acquisition of Berkeley Advanced Biomaterials (BAB) in 2017, revenue is expected to reach record highs for the 9th consecutive fiscal year. As a result, consolidated revenue is expected to increase by JPY 3,230 million compared to the previous fiscal year, to JPY 26,841 million. Profit: Deferral of the listing of consolidated subsidiary Cullgen. In the Group's pharmaceutical (Biotech) business, Cullgen Inc. ("Cullgen"), a core subsidiary, has been pursuing a listing on the NASDAQ market in the United States, subject to approval of a reverse merger transaction by the China Securities Regulatory Commission ("CSRC"). The Group had expected the review to be completed and the listing to be achieved within the fiscal year ending December 2025. However, as the approval remains pending at this time, the listing gain of JPY 22,854 million that had been included in the profit forecast for the fiscal year ending December 2025 has been excluded. Furthermore, while the initial forecast assumed Cullgen would transition to an equity-method affiliate following its listing, a change in the timing of the listing has resulted in Cullgen remaining a consolidated subsidiary for the second half of the fiscal year. Accordingly, its full-year estimated operating loss of JPY 3,996 million is now reflected in this revised forecast. Impairment Losses: As a result of impairment tests conducted by an independent third-party firm, the recoverable amounts of goodwill related to MICREN Healthcare Co. Ltd., intangible assets related to Shanghai Genomics Technology Ltd., and fixed assets related to Shanghai Rui Fu International Trade Co. Ltd. were determined to be below their carrying amounts, and an impairment loss totaling JPY 468 million is expected to be recognized. Furthermore, with respect to the transaction review related to Cullgen's listing, the approval process remains ongoing. As disclosed on December 19, 2025, the Group is continuing its efforts toward the early realization of the listing while considering alternative options. If the listing is realized in the future, any listing gain will be recognized in the financial results for the accounting period in which the listing occurs; however, the actual amount of such gain will vary depending on the initial public offering price on the listing date as well as foreign exchange movements.
お知らせ • Jan 10GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd.GNI Group Ltd. (TSE:2160) acquired ZOO LABO Co., Ltd. on December 29, 2025. A cash consideration will be paid by GNI Group Ltd towards common equity of ZOO LABO Co., Ltd. The funds were sourced from the proceeds raised through the overseas public offering conducted in July 2025. GNI Group Ltd. (TSE:2160) completed the acquisition of ZOO LABO Co., Ltd. on December 29, 2025.
分析記事 • Jan 05Does GNI Group (TSE:2160) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Dec 27GNI Group Ltd. to Report Fiscal Year 2025 Results on Feb 13, 2026GNI Group Ltd. announced that they will report fiscal year 2025 results on Feb 13, 2026
Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: JP¥7.84 (vs JP¥19.48 in 3Q 2024)Third quarter 2025 results: EPS: JP¥7.84 (down from JP¥19.48 in 3Q 2024). Revenue: JP¥7.11b (up 30% from 3Q 2024). Net income: JP¥420.0m (down 57% from 3Q 2024). Profit margin: 5.9% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
お知らせ • Sep 27GNI Group Ltd. to Report Q3, 2025 Results on Nov 14, 2025GNI Group Ltd. announced that they will report Q3, 2025 results on Nov 14, 2025
Reported Earnings • Aug 15Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2025 results: JP¥7.62 loss per share (improved from JP¥22.48 loss in 2Q 2024). Revenue: JP¥6.93b (up 20% from 2Q 2024). Net loss: JP¥384.7m (loss narrowed 66% from 2Q 2024). Revenue missed analyst estimates by 49%. Earnings per share (EPS) exceeded analyst estimates by 93%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 21% per year.
お知らせ • Jul 23GNI Group Ltd. has filed a Follow-on Equity Offering.GNI Group Ltd. has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 4,000,000
分析記事 • Jul 01GNI Group (TSE:2160) Has Debt But No Earnings; Should You Worry?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Jun 27GNI Group Ltd. to Report Q2, 2025 Results on Aug 14, 2025GNI Group Ltd. announced that they will report Q2, 2025 results on Aug 14, 2025
お知らせ • Jun 05Gyre Pharmaceuticals Co., Ltd. Announces Launch of Etorel (Nintedanib Esilate Soft Capsules) by Gyre PharmaceuticalsGNI Group Ltd. announced that its core subsidiary, Gyre Pharmaceuticals Co. Ltd., has commenced sales of "Etorel" (Nintedanib Esilate Soft Capsules), as announced on May 8, 2024, in the press release titled "Notice Regarding License Agreement entered into by GNI's Consolidated Subsidiary, Gyre Pharmaceuticals Co. Ltd., as it has secured the only two approved drugs for pulmonary fibrosis worldwide. This achievement has strategic significance in strengthening its position as a global leading company in the treatment of pulmonary fibrosis, continuously expanding its market share, and enhancing its presence in the field of interstitial lung diseases. The market for pulmonary fibrosis is large, with many unmet clinical needs remaining. Nintedanib Esilates Soft Capsules are approved not only for idiopathic pulmonary fibrosis (IPF), but also for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and progressive fibrosing interstitial lung disease (PF-ILD). The impact of this development on the company's performance has already been factored into the current consolidated earnings forecast. The impact of this development on The company's performance has already beenfactored into the current consolidated earnings forecasts. The impact of this development On the company's performance has already be factored into the current consolidated Earn forecast. The impact of this develop on the company's performance has also been factored into the current consolidate earnings forecast. The impact of This development on the company's performance have already been factored into the currently consolidated earnings forecast. The impact the development on the company's performance is already been factored into the existing consolidated earnings forecast.
Price Target Changed • May 27Price target increased by 11% to JP¥4,000Up from JP¥3,600, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of JP¥4,110. Stock is up 96% over the past year. The company is forecast to post earnings per share of JP¥215 for next year compared to JP¥21.96 last year.
分析記事 • May 26GNI Group Ltd.'s (TSE:2160) Shares Bounce 52% But Its Business Still Trails The IndustryGNI Group Ltd. ( TSE:2160 ) shareholders are no doubt pleased to see that the share price has bounced 52% in the last...
Reported Earnings • May 17First quarter 2025 earnings released: JP¥10.56 loss per share (vs JP¥29.17 profit in 1Q 2024)First quarter 2025 results: JP¥10.56 loss per share (down from JP¥29.17 profit in 1Q 2024). Revenue: JP¥5.32b (down 11% from 1Q 2024). Net loss: JP¥530.0m (down 137% from profit in 1Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth.
Major Estimate Revision • May 15Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from JP¥48.7b to JP¥43.0b. EPS estimate increased from JP¥195 to JP¥217 per share. Net income forecast to grow 869% next year vs 6.9% growth forecast for Biotechs industry in Japan. Consensus price target down from JP¥3,850 to JP¥3,600. Share price rose 3.5% to JP¥2,396 over the past week.
分析記事 • Apr 11GNI Group Ltd. (TSE:2160) Might Not Be As Mispriced As It Looks After Plunging 28%Unfortunately for some shareholders, the GNI Group Ltd. ( TSE:2160 ) share price has dived 28% in the last thirty days...
お知らせ • Apr 10GNI Group Ltd. to Report Q1, 2025 Results on May 15, 2025GNI Group Ltd. announced that they will report Q1, 2025 results on May 15, 2025
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorates as stock falls 29%After last week's 29% share price decline to JP¥1,490, the stock trades at a forward P/E ratio of 8x. Average trailing P/E is 31x in the Biotechs industry in Asia. Total returns to shareholders of 13% over the past three years.
Reported Earnings • Apr 05Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: JP¥21.96 (down from JP¥170 in FY 2023). Revenue: JP¥23.6b (down 9.2% from FY 2023). Net income: JP¥1.10b (down 86% from FY 2023). Profit margin: 4.7% (down from 31% in FY 2023). Revenue missed analyst estimates by 35%. Earnings per share (EPS) also missed analyst estimates by 88%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Feb 27Now 23% undervaluedOver the last 90 days, the stock has risen 4.5% to JP¥3,450. The fair value is estimated to be JP¥4,465, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 69%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings are also forecast to grow by 34% per annum over the same time period.
分析記事 • Feb 26GNI Group's (TSE:2160) Weak Earnings May Only Reveal A Part Of The Whole PictureThe subdued market reaction suggests that GNI Group Ltd.'s ( TSE:2160 ) recent earnings didn't contain any surprises...
分析記事 • Feb 21GNI Group Ltd.'s (TSE:2160) Shares Leap 25% Yet They're Still Not Telling The Full StoryDespite an already strong run, GNI Group Ltd. ( TSE:2160 ) shares have been powering on, with a gain of 25% in the last...
お知らせ • Feb 18GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2025GNI Group Ltd. provided consolidated earnings guidance for the full year ending December 31, 2025. For the year, the company expects revenue of JPY 28,733 million, operating profit of JPY 23,217 million, profit for the year of JPY 15,868 million and basic earnings per share of JPY 240.42.
分析記事 • Feb 18GNI Group Ltd. Just Missed Earnings - But Analysts Have Updated Their ModelsGNI Group Ltd. ( TSE:2160 ) missed earnings with its latest annual results, disappointing overly-optimistic...
お知らせ • Feb 17GNI Group Ltd., Annual General Meeting, Mar 27, 2025GNI Group Ltd., Annual General Meeting, Mar 27, 2025.
Reported Earnings • Feb 17Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: JP¥19.54 (down from JP¥170 in FY 2023). Revenue: JP¥23.6b (down 9.2% from FY 2023). Net income: JP¥977.0m (down 88% from FY 2023). Profit margin: 4.1% (down from 31% in FY 2023). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 35%. Earnings per share (EPS) also missed analyst estimates by 89%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 03GNI Group Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025GNI Group Ltd. announced that they will report fiscal year 2024 results on Feb 14, 2025
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥3,295, the stock trades at a forward P/E ratio of 15x. Average trailing P/E is 22x in the Biotechs industry in Japan. Total returns to shareholders of 132% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥1,749 per share.
Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: JP¥19.48 (vs JP¥11.67 in 3Q 2023)Third quarter 2024 results: EPS: JP¥19.48 (up from JP¥11.67 in 3Q 2023). Revenue: JP¥5.46b (down 15% from 3Q 2023). Net income: JP¥975.0m (up 76% from 3Q 2023). Profit margin: 18% (up from 8.6% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 01GNI Group Ltd. to Report Q3, 2024 Results on Nov 14, 2024GNI Group Ltd. announced that they will report Q3, 2024 results on Nov 14, 2024
分析記事 • Sep 20After Leaping 48% GNI Group Ltd. (TSE:2160) Shares Are Not Flying Under The RadarGNI Group Ltd. ( TSE:2160 ) shareholders would be excited to see that the share price has had a great month, posting a...
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 19%After last week's 19% share price gain to JP¥2,495, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 17x in the Biotechs industry in Japan. Total returns to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥1,655 per share.
分析記事 • Aug 27GNI Group's (TSE:2160) Shareholders Should Assess Earnings With CautionDespite posting strong earnings, GNI Group Ltd.'s ( TSE:2160 ) stock didn't move much over the last week. We looked...
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to JP¥2,241, the stock trades at a forward P/E ratio of 10x. Average trailing P/E is 14x in the Biotechs industry in Japan. Total returns to shareholders of 40% over the past three years.
Reported Earnings • Aug 17Second quarter 2024 earnings released: EPS: JP¥3.31 (vs JP¥34.98 in 2Q 2023)Second quarter 2024 results: EPS: JP¥3.31 (down from JP¥34.98 in 2Q 2023). Revenue: JP¥5.87b (down 41% from 2Q 2023). Net income: JP¥165.1m (down 90% from 2Q 2023). Profit margin: 2.8% (down from 17% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 07Investor sentiment deteriorates as stock falls 24%After last week's 24% share price decline to JP¥1,732, the stock trades at a forward P/E ratio of 9x. Average trailing P/E is 51x in the Biotechs industry in Japan. Total returns to shareholders of 3.0% over the past three years.
分析記事 • Aug 06GNI Group Ltd. (TSE:2160) Stock's 37% Dive Might Signal An Opportunity But It Requires Some ScrutinyGNI Group Ltd. ( TSE:2160 ) shareholders that were waiting for something to happen have been dealt a blow with a 37...
New Risk • Aug 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). High level of non-cash earnings (41% accrual ratio). Minor Risk Shareholders have been diluted in the past year (5.4% increase in shares outstanding).
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥2,233, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 94x in the Biotechs industry in Japan. Total returns to shareholders of 21% over the past three years.
分析記事 • Jun 20Investors Continue Waiting On Sidelines For GNI Group Ltd. (TSE:2160)GNI Group Ltd.'s ( TSE:2160 ) price-to-sales (or "P/S") ratio of 4.4x might make it look like a strong buy right now...
お知らせ • Jun 02GNI Group Ltd. to Report Q2, 2024 Results on Aug 14, 2024GNI Group Ltd. announced that they will report Q2, 2024 results on Aug 14, 2024
Board Change • May 19High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Executive officer, CFO & Director Toshiya Kitagawa was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Apr 12Is GNI Group (TSE:2160) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
お知らせ • Mar 27GNI Group Ltd. to Report Q1, 2024 Results on May 15, 2024GNI Group Ltd. announced that they will report Q1, 2024 results on May 15, 2024
分析記事 • Mar 19News Flash: Analysts Just Made An Incredible Upgrade To Their GNI Group Ltd. (TSE:2160) ForecastsGNI Group Ltd. ( TSE:2160 ) shareholders will have a reason to smile today, with the covering analyst making...
Major Estimate Revision • Mar 19Consensus revenue estimates increase by 38%The consensus outlook for revenues in fiscal year 2024 has improved. 2024 revenue forecast increased from JP¥28.8b to JP¥39.6b. EPS estimate increased from JP¥37.00 to JP¥143 per share. Net income forecast to shrink 12% next year vs 25% growth forecast for Biotechs industry in Japan . Consensus price target up from JP¥3,000 to JP¥4,100. Share price rose 2.8% to JP¥3,130 over the past week.
分析記事 • Feb 28Further Upside For GNI Group Ltd. (TSE:2160) Shares Could Introduce Price Risks After 40% BounceGNI Group Ltd. ( TSE:2160 ) shares have had a really impressive month, gaining 40% after a shaky period beforehand. The...
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment improves as stock rises 43%After last week's 43% share price gain to JP¥3,615, the stock trades at a forward P/E ratio of 98x. Average trailing P/E is 69x in the Biotechs industry in Japan. Total returns to shareholders of 92% over the past three years.
Reported Earnings • Feb 16Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: EPS: JP¥170 (up from JP¥8.17 in FY 2022). Revenue: JP¥26.0b (up 49% from FY 2022). Net income: JP¥8.09b (up JP¥7.71b from FY 2022). Profit margin: 31% (up from 2.2% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates significantly. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 15GNI Group Ltd., Annual General Meeting, Mar 28, 2024GNI Group Ltd., Annual General Meeting, Mar 28, 2024.
New Risk • Dec 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Shareholders have been diluted in the past year (4.7% increase in shares outstanding).
お知らせ • Dec 05GNI Group Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024GNI Group Ltd. announced that they will report fiscal year 2023 results on Feb 14, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: JP¥11.67 (vs JP¥8.40 in 3Q 2022)Third quarter 2023 results: EPS: JP¥11.67 (up from JP¥8.40 in 3Q 2022). Revenue: JP¥6.45b (up 40% from 3Q 2022). Net income: JP¥554.0m (up 39% from 3Q 2022). Profit margin: 8.6% (down from 8.7% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
お知らせ • Sep 29+ 1 more updateGNI Group Ltd. Announces New Management StructureGNI Group Co. Ltd. announced that Board of Directors has resolved at a meeting on September 28, 2023 to change the responsibilities of directors and executive officers effective October 1, 2023. Change of the responsibilities of directors and executive officers: Kan-ichiro Suzuki is now Director, Executive Officer, Vice President from previous position of Director, Executive Officer, CFO (Chief Financial Officer) and Toshiya Kitagawa is now Executive Officer, CFO (Chief Financial Officer) from previous position of Executive Officer, CSO (Chief Strategy Officer).
Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 44%After last week's 44% share price gain to JP¥1,970, the stock trades at a forward P/E ratio of 122x. Average forward P/E is 29x in the Biotechs industry in Asia. Total loss to shareholders of 25% over the past three years.
New Risk • Aug 15New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 30% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (30% accrual ratio).
Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: JP¥34.96 (vs JP¥6.85 in 2Q 2022)Second quarter 2023 results: EPS: JP¥34.96 (up from JP¥6.85 in 2Q 2022). Revenue: JP¥9.89b (up 134% from 2Q 2022). Net income: JP¥1.66b (up 411% from 2Q 2022). Profit margin: 17% (up from 7.7% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Major Estimate Revision • Aug 04Consensus EPS estimates fall by 47%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from JP¥68.00 to JP¥36.00. Revenue forecast unchanged from JP¥24.8b at last update. Net income forecast to grow 3,411% next year vs 33% growth forecast for Biotechs industry in Japan. Consensus price target of JP¥1,500 unchanged from last update. Share price rose 10% to JP¥1,346 over the past week.
お知らせ • Jul 04Gni Group Ltd. Announces Notice of Executive Officer AppointmentJuly 3, 2023, GNI Group Ltd. ("the Group") announced the appointment of Toshiya Kitagawa as Chief Strategy Officer (CSO) with the aim of accelerating the global business growth of the Group under a resolution of the Board of Directors dated on July 3, 2023. Career summary of Toshiya Kitagawa: April 2000: Japan Bond Trading Co. Ltd. April 2002: Totan ICAP Co. Ltd. February 2003: Deal Max Co. Ltd. October 2008: OAG Certified Public Tax Accountant's Corporation Business Development Manager. April 2009: Takara Leben Co. Ltd. Director, Executive Officer, General Manager of Corporate Planning Office. April 2017: Hoosiers Holdings Co. Ltd. General Manager of Group Strategy Office. January 2019: BASE Co. Ltd. CEO. March 2023: Eltes Co. Ltd. Deputy General Manager of Corporate Planning Office. July 2023: GNI Group Ltd., SO.
New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.2% net profit margin).
Reported Earnings • May 19First quarter 2023 earnings released: JP¥0.042 loss per share (vs JP¥7.40 profit in 1Q 2022)First quarter 2023 results: JP¥0.042 loss per share (down from JP¥7.40 profit in 1Q 2022). Revenue: JP¥4.21b (up 6.9% from 1Q 2022). Net loss: JP¥2.00m (down 101% from profit in 1Q 2022). Profit margin: 0% (down from 8.9% in 1Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
お知らせ • May 10Beijing Continent Achieves Mid-Point Subject Enrollment for F351 Phase III Clinical Trial in ChinaGNI Group Ltd. provided an update on the subject enrollment in Phase III clinical trial in China of F351 (generic name: Hydronidone) for HBV-induced liver fibrosis conducted by one of main subsidiaries, Beijing Continent Pharmaceuticals Co. Ltd. As of May 19, 2023, Continent has completed the enrollments of 124 subjects, which is 50% of the target enrollment.
Board Change • Apr 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Outside Director Kanako Kikuchi was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 18Full year 2022 earnings released: EPS: JP¥9.61 (vs JP¥22.72 in FY 2021)Full year 2022 results: EPS: JP¥9.61 (down from JP¥22.72 in FY 2021). Revenue: JP¥17.4b (up 37% from FY 2021). Net income: JP¥456.0m (down 57% from FY 2021). Profit margin: 2.6% (down from 8.4% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Feb 16+ 1 more updateGNI Group Ltd. to Report Fiscal Year 2022 Final Results on Mar 31, 2023GNI Group Ltd. announced that they will report fiscal year 2022 final results on Mar 31, 2023
お知らせ • Feb 15GNI Group Ltd., Annual General Meeting, Mar 30, 2023GNI Group Ltd., Annual General Meeting, Mar 30, 2023.
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥1,393, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 27x in the Biotechs industry in Asia. Total loss to shareholders of 47% over the past three years.
お知らせ • Dec 06GNI Group Ltd. to Report Fiscal Year 2022 Results on Feb 15, 2023GNI Group Ltd. announced that they will report fiscal year 2022 results on Feb 15, 2023
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: JP¥8.42 (vs JP¥7.42 in 3Q 2021)Third quarter 2022 results: EPS: JP¥8.42 (up from JP¥7.42 in 3Q 2021). Revenue: JP¥4.61b (up 50% from 3Q 2021). Net income: JP¥400.0m (up 14% from 3Q 2021). Profit margin: 8.7% (down from 12% in 3Q 2021). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 17Second quarter 2022 earnings released: EPS: JP¥6.85 (vs JP¥10.76 in 2Q 2021)Second quarter 2022 results: EPS: JP¥6.85 (down from JP¥10.76 in 2Q 2021). Revenue: JP¥4.22b (up 63% from 2Q 2021). Net income: JP¥325.0m (down 36% from 2Q 2021). Profit margin: 7.7% (down from 20% in 2Q 2021). Over the next year, revenue is forecast to grow 25%, compared to a 182% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Major Estimate Revision • Aug 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from JP¥15.7b to JP¥16.4b. EPS estimate fell from JP¥58.00 to JP¥23.13 per share. Net income forecast to grow 21% next year vs 29% growth forecast for Biotechs industry in Japan. Consensus price target of JP¥2,100 unchanged from last update. Share price was steady at JP¥1,977 over the past week.
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to JP¥1,526, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 26x in the Biotechs industry in Asia. Total returns to shareholders of 5.5% over the past three years.
Valuation Update With 7 Day Price Move • May 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to JP¥1,210, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 23x in the Biotechs industry in Asia. Total returns to shareholders of 29% over the past three years.
Price Target Changed • Apr 27Price target decreased to JP¥2,100Down from JP¥2,500, the current price target is provided by 1 analyst. New target price is 82% above last closing price of JP¥1,156. Stock is down 43% over the past year. The company is forecast to post earnings per share of JP¥58.00 for next year compared to JP¥22.72 last year.
Reported Earnings • Apr 02Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: JP¥22.72 (down from JP¥28.96 in FY 2020). Revenue: JP¥12.7b (up 30% from FY 2020). Net income: JP¥1.07b (down 15% from FY 2020). Profit margin: 8.4% (down from 13% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 27%. Over the next year, revenue is forecast to grow 24%, compared to a 3,392% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥1,416, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 29x in the Biotechs industry in Asia. Total returns to shareholders of 43% over the past three years.
Reported Earnings • Feb 16Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: JP¥22.72 (down from JP¥28.96 in FY 2020). Revenue: JP¥12.7b (up 30% from FY 2020). Net income: JP¥1.07b (down 15% from FY 2020). Profit margin: 8.4% (down from 13% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 27%. Over the next year, revenue is forecast to grow 24%, compared to a 1,669% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to JP¥1,193, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 27x in the Biotechs industry in Asia. Total returns to shareholders of 11% over the past three years.
Reported Earnings • Nov 18Third quarter 2021 earnings released: EPS JP¥7.44 (vs JP¥5.11 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥3.07b (up 19% from 3Q 2020). Net income: JP¥353.0m (up 59% from 3Q 2020). Profit margin: 12% (up from 8.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to JP¥1,586, the stock trades at a trailing P/E ratio of 44.8x. Average trailing P/E is 36x in the Biotechs industry in Japan. Total returns to shareholders of 44% over the past three years.
Reported Earnings • Apr 06Full year 2020 earnings released: EPS JP¥28.96 (vs JP¥4.28 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥9.77b (up 31% from FY 2019). Net income: JP¥1.26b (up JP¥1.08b from FY 2019). Profit margin: 13% (up from 2.4% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥2,315, the stock trades at a trailing P/E ratio of 79.9x. Average trailing P/E is 112x in the Biotechs industry in Japan. Total returns to shareholders of 27% over the past three years.
Reported Earnings • Feb 14Full year 2020 earnings released: EPS JP¥25.05 (vs JP¥4.28 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: JP¥9.77b (up 31% from FY 2019). Net income: JP¥1.09b (up JP¥907.0m from FY 2019). Profit margin: 11% (up from 2.4% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 22New 90-day high: JP¥2,179The company is up 3.0% from its price of JP¥2,108 on 23 October 2020. The Japanese market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.
